Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Flagged first, then by citations

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 601–700 of 1,004

Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation
Ahmed, M. B., Islam, S. U., Alghamdi, A. A. A., Kamran, M., Ahsan, H., & Lee, Y. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415765 · Cited by 99
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 93
The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis
Fusella, F., Seclì, L., Busso, E., Křepelová, A., Moiso, E., Rocca, S., Conti, L., Annaratone, L., Rubinetto, C., Grand, M. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01829-1 · Cited by 92
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
Murthy, D., Attri, K. S., & Singh, P. K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00335 · Cited by 96
A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity
Watkins-Schulz, R., Tiet, P., Gallovic, M. D., Junkins, R. D., Batty, C. J., Bachelder, E. M., Ainslie, K. M., & Ting, J. P. ‐. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.011 · Cited by 91
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 93
Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Liu, Q., Duo, Y., Fu, J., Qiu, M., Sun, Z., Adah, D., Kang, J., Xie, Z., Fan, T., Bao, S., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101023 · Cited by 93
Potential of Magnetic Hyperthermia to Stimulate Localized Immune Activation
Carter, T. J., Agliardi, G., Lin, F., Ellis, M. J., Jones, C. L., Robson, M. P., Richard-Loendt, A., Southern, P., Lythgoe, M. F., Thin, M. Z., et al. (2021) · Small · doi:10.1002/smll.202005241 · Cited by 92
Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy
Xiong, X., Zhao, J., Su, R., Liu, C., Guo, X., & Zhou, S. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101225 · Cited by 94
Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis
Peela, N., Truong, D. D., Saini, H., Chu, H., Mashaghi, S., Ham, S. L., Singh, S. K., Tavana, H., Mosadegh, B., & Nikkhah, M. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.017 · Cited by 97
Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core–shell nanoparticles for enhanced tumor-localized chemoimmunotherapy
Wang, T., Zhang, J., Hou, T., Yin, X., & Zhang, N. (2019) · Nanoscale · doi:10.1039/c9nr03374b · Cited by 91
The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation
Han, C., Godfrey, V., Liu, Z., Han, Y., Liu, L., Peng, H., Weichselbaum, R. R., Zaki, H., & Fu, Y. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc6998 · Cited by 92
Self-citation
Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity
Faramarzi, F., Zafari, P., Alimohammadi, M., Moonesi, M., Rafiei, A., & Bekeschus, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9916796 · Cited by 98
Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression
Xu, Y., Yan, J., Tao, Y., Qian, X., Zhang, C., Yin, L., Gu, P., Liu, Y., Pan, Y., Tang, R., et al. (2022) · Science · doi:10.1126/science.abj2674 · Cited by 94
Metal-based nanoparticle in cancer treatment: lessons learned and challenges
Hheidari, A., Mohammadi, J., Ghodousi, M., Mahmoodi, M., Ebrahimi, S., Pishbin, E., & Rahdar, A. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1436297 · Cited by 101
Local iron homeostasis in the breast ductal carcinoma microenvironment
Marques, O., Porto, G., Rêma, A., Faria, F., Cruz Paula, A., Gomez-Lazaro, M., Silva, P., Martins da Silva, B., & Lopes, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2228-y · Cited by 90
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
Wu, S.-Y., Xiao, Y., Wei, J., Xu, X., Jin, X., Hu, X., Li, D., Jiang, Y., & Shao, Z.-M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002528 · Cited by 93
Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy
Peng, B., Nguyen, T. M., Jayasinghe, M. K., Gao, C. J., Pham, T. T., Vu, L. T., Yeo, E. Y. M., Yap, G. L. R., Wang, L., Goh, B. C., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12187 · Cited by 90
Exploration of the platelet proteome in patients with early-stage cancer
Sabrkhany, S., Kuijpers, M. J. E., Knol, J. C., Damink, S. W. M. O., Dingemans, A. C., Verheul, H. M. W., Piersma, S. R., Pham, T. V., Griffioen, A. W., Egbrink, M. G. A. O., et al. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.02.011 · Cited by 89
Neuropilins in the Context of Tumor Vasculature
Niland, S., & Eble, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030639 · Cited by 91
The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance
Chang, R. B., & Beatty, G. L. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0320-475r · Cited by 99
Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment
Wang, X., Duanmu, J., Fu, X., Li, T., & Jiang, Q. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02491-w · Cited by 91
Mathematical model of tumor–immune surveillance
Mahasa, K. J., Ouifki, R., Eladdadi, A., & de Pillis, L. G. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.06.012 · Cited by 90
High intratumoral CD8 + T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy
Yang, Y., Attwood, K., Bshara, W., Mohler, J. L., Guru, K., Xu, B., Kalinski, P., & Chatta, G. (2021) · The Prostate · doi:10.1002/pros.24068 · Cited by 88
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation
Janowski, A. M., Colegio, O. R., Hornick, E. E., McNiff, J. M., Martin, M. D., Badovinac, V. P., Norian, L. A., Zhang, W., Cassel, S. L., & Sutterwala, F. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86953 · Cited by 94
Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma
de Assis, L. V. M., Kinker, G. S., Moraes, M. N., Markus, R. P., Fernandes, P. A. C. M., & Castrucci, A. M. D. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00185 · Cited by 91
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
Risk factor analysis and nomogram for predicting in-hospital mortality in ICU patients with sepsis and lung infection
Ren, Y., Zhang, L., Xu, F., Han, D., Zheng, S., Zhang, F., Li, L., Wang, Z., Lyu, J., & Yin, H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01809-8 · Cited by 90
The interactions of paclitaxel with tumour microenvironment
Yu, D., Lou, Z., Ma, F.-Y., & Najafi, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108555 · Cited by 93
Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
Westdorp, H., Sköld, A. E., Snijer, B. A., Franik, S., Mulder, S. F., Major, P. P., Foley, R., Gerritsen, W. R., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00191 · Cited by 92
Rho, ROCK and actomyosin contractility in metastasis as drug targets
Rodríguez‐Hernández, I., Cantelli, G., Fanshawe, B., & Sanz‐Moreno, V. (2016) · F1000Research · doi:10.12688/f1000research.7909.1 · Cited by 90
Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy
Kallert, S. M., Darbre, S., Bonilla, W. V., Kreutzfeldt, M., Pagé, N., Müller, P., Kreuzaler, M., Lu, M., Favre, S., Kreppel, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms15327 · Cited by 84
Clinically feasible approaches to potentiating cancer cell-based immunotherapies
Seledtsov, V. I., Гончаров, А. Г., & Seledtsova, G. V. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1009814 · Cited by 87
Oxygen in the tumor microenvironment: effects on dendritic cell function
Paardekooper, L. M., de Vos, W., & van den Bogaart, G. (2019) · Oncotarget · doi:10.18632/oncotarget.26608 · Cited by 89
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 87
SPP1+ macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-α and IL-1β
Liu, C., Wu, K., Li, C., Zhang, Z., Zhai, P., Guo, H., & Zhang, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03255-w · Cited by 87
From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy
Deng, L., Liang, H. L., Fu, S., Weichselbaum, R. R., & Fu, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3110 · Cited by 87
Self-citation
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model
Mitchell, L., Espinoza, F. L., Mendoza, D., Kato, Y., Inagaki, A., Hiraoka, K., Kasahara, N., Gruber, H. E., Jolly, D. J., & Robbins, J. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox037 · Cited by 86
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 88
Pancreatic cancer‐derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK‐mediated endoplasmic reticulum stress
Shen, T., Huang, Z., Shi, C., Pu, X., Xu, X., Wu, Z., Ding, G., & Cao, L. (2020) · The FASEB Journal · doi:10.1096/fj.201902186r · Cited by 88
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
Morita, M., Nishida, N., Sakai, K., Aoki, T., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., et al. (2021) · Liver Cancer · doi:10.1159/000516899 · Cited by 90
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130
Badve, S., Penault-Llorca, F. M., Reis-Filho, J. S., Deurloo, R., Siziopikou, K. P., D’Arrigo, C., & Viale, G. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab121 · Cited by 86
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 89
JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis
Chen, S., Wang, M., Lu, T., Liu, Y., Hong, W., He, X., Cheng, Y., Liu, J., Wei, Y., & Wei, X. (2023) · Oncogene · doi:10.1038/s41388-023-02781-9 · Cited by 86
Artificial intelligence-based models enabling accurate diagnosis of ovarian cancer using laboratory tests in China: a multicentre, retrospective cohort study
Cai, G., Huang, F., Gao, Y., Li, X., Chi, J., Xie, J., Zhou, L., Feng, Y., Huang, H., Deng, T., et al. (2024) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00245-5 · Cited by 86
Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
Spaapen, R. M., Leung, M. Y. K., Fuertes, M. B., Kline, J. P., Zhang, L., Zheng, Y., Fu, Y., Luo, X., Cohen, K. S., & Gajewski, T. F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401109 · Cited by 86
Self-citation
A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)
Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., TAHARA, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 87
Tumor metabolism, cancer cell transporters, and microenvironmental resistance
Alfarouk, K. O. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1140753 · Cited by 88
Nerve growth factor: role in growth, differentiation and controlling cancer cell development
Aloe, L., Rocco, M. L., Balzamino, B. O., & Micera, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0395-y · Cited by 86
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
Bassiri, H., Benavides, A. D., Haber, M., Gilmour, S. K., Norris, M. D., & Hogarty, M. D. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.06 · Cited by 87
Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis
Al-Qadami, G. H., Sebille, Y. Z. A. V., Le, H. V., & Bowen, J. M. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1595586 · Cited by 87
Progress in Nanorobotics for Advancing Biomedicine
Li, M., Xi, N., Wang, Y., & Liu, L. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.2990380 · Cited by 86
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Dong, H., Li, Q., Zhang, Y., Ding, M., Teng, Z., & Mou, Y. (2023) · Advanced Science · doi:10.1002/advs.202301339 · Cited by 87
The role of dendritic cells in cancer
Hansen, M., & Andersen, M. H. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0592-y · Cited by 88
Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity
Janji, B., Berchem, G., & Chouaı̈b, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00887 · Cited by 86
Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma
Xu, X., Tan, Y., Qian, Y., Xue, W., Wang, Y., Du, J., Jin, L., & Ding, W. (2019) · Medicine · doi:10.1097/md.0000000000013923 · Cited by 84
Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD‐1 receptor
Tumino, N., Martini, S., Munari, E., Scordamaglia, F., Besi, F., Mariotti, F. R., Bogina, G. S., Mingari, M. C., Vacca, P., & Moretta, L. (2019) · International Journal of Cancer · doi:10.1002/ijc.32262 · Cited by 84
The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
Liu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 87
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Ribeiro, R., Carvalho, M. J., Gonçalves, J., & Moreira, J. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.903065 · Cited by 86
The function of natural compounds in important anticancer mechanisms
Nan, Y., Su, H., Zhou, B., & Liu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1049888 · Cited by 88
Rationale for anti-CD137 cancer immunotherapy
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.026 · Cited by 84
Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like
Giannini, R., Moretti, S., Ugolini, C., Macerola, E., Menicali, E., Nucci, N., Morelli, S., Colella, R., Mandarano, M., Sidoni, A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01167 · Cited by 85
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
Machiels, J., Gomez‐Roca, C., Michot, J., Zamarin, D., Mitchell, T. C., Catala, G., Eberst, L., Jacob, W., Jegg, A.-M., Cannarile, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001153 · Cited by 83
TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer
Liang, R., Zhu, X., Lan, T., Ding, D., Zheng, Z., Chen, T., Huang, Y. L., Liu, J., Yang, X., Shao, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02886-8 · Cited by 83
NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
Wen, T., Barham, W. J., Li, Y., Zhang, H., Gicobi, J. K., Hirdler, J. B., Liu, X., Ham, H., Martinez, K., Lucien, F., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0539 · Cited by 83
Immunotherapy and immunoevasion of colorectal cancer
Zein, M. A., Boukhdoud, M., Shammaa, H., Mouslem, H., Ayoubi, L. M. E., Iratni, R., Issa, K., Khachab, M. Y., Assi, H. I., Sahebkar, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103669 · Cited by 88
cGAS-STING signaling in the tumor microenvironment
Liu, Z., Wang, D., Zhang, J., Xiang, P., Zeng, Z., Xiong, W., & Shi, L. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216409 · Cited by 87
A Metabolism Toolbox for CAR T Therapy
Xu, X., Gnanaprakasam, J. R., Sherman, J. W., & Wang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00322 · Cited by 82
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 84
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 84
Integrated cancer tissue engineering models for precision medicine
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Raghavan, S. A., Snyder, C. S., & Mehta, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216564 · Cited by 84
The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer
Barriga, V., Kuol, N., Nurgali, K., & Apostolopoulos, V. (2019) · Cancers · doi:10.3390/cancers11081205 · Cited by 86
Tumor immune response and immunotherapy in gastric cancer
Kwak, Y., Seo, A. N., Lee, H. E., & Lee, H. S. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.10.08 · Cited by 83
Relationship between Fusobacterium nucleatum and antitumor immunity in colorectal cancer liver metastasis
Sakamoto, Y., Mima, K., Ishimoto, T., Ogata, Y., Imai, K., Miyamoto, Y., Akiyama, T., Daitoku, N., Hiyoshi, Y., Iwatsuki, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15126 · Cited by 85
Glioblastoma Microenvironment and Cellular Interactions
Crivii, C.-B., Boșca, A. B., Melincovici, C. S., Constantin, A.-M., Mărginean, M., Dronca, E., Suflețel, R., Gonciar, D., Bungărdean, M., & Șovrea, A. (2022) · Cancers · doi:10.3390/cancers14041092 · Cited by 81
The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment
Aguilar‐Cázares, D., Chavez-Dominguez, R., Marroquin-Muciño, M., Perez-Medina, M., Benito-Lopez, J. J., Camarena, Á., Rumbo‐Nava, U., & López-González, J. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.929572 · Cited by 85
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment
Onkar, S., Cui, J., Zou, J., Cardello, C., Cillo, A. R., Uddin, M. R., Sagan, A., Joy, M., Osmanbeyoglu, H. U., Pogue–Geile, K. L., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00527-w · Cited by 82
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 95
Tumour islet Foxp3+T-cell infiltration predicts poor outcome in nonsmall cell lung cancer
O’Callaghan, D. S., Rexhepaj, E., Gately, K. A., Coate, L. E., Delaney, D., O’Donnell, D. M., Kay, E. W., O’Connell, F., Gallagher, W. M., & O'Byrne, K. J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00176-2014 · Cited by 87
Insights into the role of IL-32 in cancer
Sloot, Y. J. E., Smit, J. W. A., Joosten, L. A. B., & Netea-Maier, R. T. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.03.004 · Cited by 82
The current landscape of 3D in vitro tumor models: what cancer hallmarks are accessible for drug discovery?
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response
Lehmann, B., Biburger, M., Brückner, C., Ipsen-Escobedo, A., Gordan, S., Lehmann, C. H. K., Voehringer, D., Winkler, T., Schaft, N., Dudziak, D., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah6413 · Cited by 87
Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression
Zhang, Q., Lou, Y., Bai, X., & Liang, T. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3500 · Cited by 81
Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing
Liu, J., Zhou, G., Li, Z., & Zhao, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00456 · Cited by 84
Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway
Masjedi, A., Hassannia, H., Atyabi, F., Rastegari, A., Hojjat‐Farsangi, M., Namdar, A., Soleimanpour, H., Azizi, G., Nikkhoo, A., Ghalamfarsa, G., et al. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.223 · Cited by 82
Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s
Wagner, M., Ealey, K. N., Tetsu, H., Kiniwa, T., Motomura, Y., Moro, K., & Koyasu, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.103 · Cited by 83
Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment
Friedman, K. A., Brodsky, A. S., Lu, S., Wood, S., Gill, A. J., Lombardo, K. A., Yang, D., & Resnick, M. B. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.54 · Cited by 84
Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli
Chuang, Y., Hung, M. E., Cangelose, B. K., & Leonard, J. N. (2016) · Innate Immunity · doi:10.1177/1753425916668243 · Cited by 85
Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA–seq data
Li, B., Li, T., Wang, B., Dou, R., Pignon, J.-C., Choueiri, T. K., Signoretti, S., Liu, J. S., & Liu, X. S. (2017) · Nature Genetics · doi:10.1038/ng.3820 · Cited by 80
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
Dahal, L. N., Dou, L., Hussain, K., Liu, R., Earley, A., Cox, K. L., Murinello, S., Tracy, I., Forconi, F., Steele, A. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2784 · Cited by 83
Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer
van Hooren, L., Sandin, L. C., Moskalev, I., Ellmark, P., Dimberg, A., Black, P. C., Tötterman, T. H., & Mangsbo, S. M. (2016) · European Journal of Immunology · doi:10.1002/eji.201646583 · Cited by 79
Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis
Zhu, T., Bao, X., Chen, M., Lin, R., Zhuyan, J., Zhen, T., Xing, K., Zhou, W. J., & Zhu, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.585284 · Cited by 85
Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape
Sharma, P., Zhang, X., Ly, K., Kim, J. H., Wan, Q., Kim, J., Lou, M., Kain, L., Teyton, L., & Winau, F. (2024) · Science · doi:10.1126/science.adg1955 · Cited by 85
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Soliman, H. H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s122974 · Cited by 81
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice
Gagliato, D. D. M., Cortés, J., Curigliano, G., Loi, S., Denkert, C., Pérez-García, J. M., & Holgado, E. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.003 · Cited by 80
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 79
Anti‐angiogenic effects of CD73‐specific siRNA‐loaded nanoparticles in breast cancer‐bearing mice
Ghalamfarsa, G., Rastegari, A., Atyabi, F., Hassannia, H., Hojjat‐Farsangi, M., Ghanbari, A., Anvari, E., Mohammadi, J., Azizi, G., Masjedi, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26743 · Cited by 81
Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion
Rhost, S., Hughes, É., Harrison, H., Rafnsdóttir, S., Jacobsson, H., Gregersson, P., Magnusson, Y., Fitzpatrick, P., Andersson, D., Berger, K., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1060-5 · Cited by 85
Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
Manukian, G., Bar‐Ad, V., Lü, B., Argiris, A. E., & Johnson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00122 · Cited by 83
Inflammasome inhibitors: promising therapeutic approaches against cancer
Xu, S., Li, X., Liu, Y., Xia, Y., Chang, R., & Zhang, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0755-0 · Cited by 80

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks